Skip to main content

Table 1 Multivariable logistic regression analyses predicting PrEP discussion with peers

From: Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians

 

ALL GENDERSa

N = 166/1405

FEMALEb

n = 43/379

MALEc

n = 119/1009

 

N (%)

AOR

(95% CI)

p-value

n (%)

AOR

(95% CI)

p-value

n (%)

AOR

(95% CI)

p-value

Age (years)

 < 30

12 (16.7)

1.5

0.7–2.9

     

8 (17.8)

1.3

0.5–3.0

0.568

 30–40

45 (16.7)

1.6

1.0–2.3

0.034

    

32 (18.1)

1.7

1.1–2.8

0.026

 > 40

109 (10.2)

1

      

79 (10.0)

1

  

Socio-economic category

 Without occupation

30 (11.3)

1

  

7 (6.2)

1

  

21 (14.8)

1

  

 Farmers/Intermediary workers

47 (9.4)

0.9

0.5–1.4

0.659

12 (10.7)

1.7

0.6–4.7

0.316

33 (8.5)

0.6

0.3–1.1

0.087

 Employee/Intellectual workers

72 (16.9)

1.7

1.0–2.7

0.036

19 (17.8)

3.8

1.4–10.2

0.007

53 (16.7)

1.2

0.6–2.1

0.608

 Retired

17 (8.1)

0.8

0.4–1.6

0.549

5 (10.6)

1.7

0.5–6

0.395

12 (7.3)

0.6

0.3–1.3

0.189

Member of HIV associations

 Yes

51 (21.3)

2.4

1.6–3.5

<0.001

11 (19.0)

2.4

1.1–5.4

0.028

37 (21.1)

2.4

1.6–3.8

<0.001

Undetectable HIV RNA

 No

    

14 (20.3)

2.5

1.1–5.3

0.023

    

Route of HIV transmission

 Heterosexual intercourse

41 (8.7)

1

      

19 (7.7)

1

  

 Homo/Bisexual intercourse

74 (15.8)

1.7

1.1–2.6

0.015

    

66 (15.4)

1.8

1.0–3.1

0.041

 Intravenous Drug Use

32 (14.0)

2.0

1.2–3.4

0.008

    

22 (12.9)

2.0

1.0–4.0

0.038

 Other/unknown

19 (7.9)

1.0

0.5–1.7

0.967

    

12 (7.4)

1.0

0.5–2.2

0.915

CD4 count/mm3

 < 200

21 (17.9)

2.1

1.2–3.7

0.009

7 (19.4)

2.9

1.0–8.5

0.050

    

 200–499

45 (12.0)

1.2

0.8–1.8

0.325

12 (12.5)

1.5

0.7–3.6

0.308

    

 500+

75 (11.2)

1

  

16 (8.2)

1

      

 NR/ND

25 (10.4)

1.2

0.7–2.0

0.501

8 (15.4)

2.1

0.8–5.8

0.144

    

Partners’ number (last 3 months)

 No partner

39 (8.8)

1

  

14 (9.2)

1

  

25 (8.6)

1

  

 Single partner

86 (11.7)

1.2

0.8–1.8

0.490

24 (11.2)

1.3

0.6–2.7

0.545

61 (11.8)

1.3

0.8–2.1

0.347

 Multiple partners

41 (18.1)

1.7

1.0–2.9

0.042

5 (45.5)

8.9

2.1–37.7

0.003

33 (16.4)

1.6

0.9–3.0

0.096

  1. AOR adjusted odds ratio, CI confidence interval, ART antiretroviral therapy, STI sexually transmitted infection
  2. aIncluding Transgender persons (n = 4/17). Significant variables at univariate analysis (p < 0.100): Gender (forced variable); Age; Socio-economic category; Member of HIV associations; Route of HIV transmission; CD4 count/mm3; STI (last 12 months); Partners’ number (last 3 months)
  3. bSignificant variables at univariate analysis (p < 0.100): Age (forced variable); Socio-economic category; Member of HIV associations; Undetectable HIV RNA; CD4 count/mm3; Partners’ number (last 3 months)
  4. cSignificant variables at univariate analysis (p < 0.100): Age; Place of residence; Socio-economic category; Member of HIV associations; Route of HIV transmission; Partners’ number (last 3 months)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us